Shots:
- HUTCHMED completed the pts enrollment in the global P-III (SAFFRON) study evaluating Orpathys (savolitinib) + Tagrisso (osimertinib) vs Pt. based doublet CT in pts with EGFR-mutated, MET-overexpressed, and/or amplified, LA/M NSCLC after progression on Tagrisso, with the last patient being randomized on 31 Oct’25
- The Ongoing P-III (SAFFRON) study is evaluating the efficacy and safety in a total of 338 pts over 230 sites across 29 countries. The 1EP of the study is PFS, with key 2EPs including OS, ORR, DoR, DCR, TTR, and safety
- Topline data are expected in H1’26, potentially supporting global regulatory. In June’25, based on the P-III (SACHI) study, the combination was approved in China
Ref: HUTCHMED | Image: HUTCHMED | Press Release
Related News:- HUTCHMED Reports the P-II/III (FRUSICA-2) Trial Data of Fruquintinib + Sintilimab for Renal Cell Carcinoma (RCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
